{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:50:43Z","timestamp":1790272243563,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T00:00:00Z","timestamp":1285632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/sj.bjc.6605917","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T20:05:42Z","timestamp":1285704342000},"page":"1362-1368","source":"Crossref","is-referenced-by-count":26,"title":["A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours"],"prefix":"10.1038","volume":"103","author":[{"given":"C M L","family":"van Herpen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F A L M","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Desar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Hooftman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J N H","family":"Timmer-Bonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,28]]},"reference":[{"key":"BF6605917_CR1","unstructured":"Bristol Myers Squibb (SPC) (2005) Taxol Summary of Product Characteristics. Report. Bristol Myers Squibb: UK"},{"key":"BF6605917_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.hfc.2005.06.013","volume":"1","author":"F Ginsberg","year":"2005","unstructured":"Ginsberg F, Parrillo JE (2005) Eosinophilic myocarditis. Heart Fail Clin 1: 419\u2013429","journal-title":"Heart Fail Clin"},{"issue":"8","key":"BF6605917_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7 (8): 1041\u20131053. Review","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"BF6605917_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/95.8.605","volume":"95","author":"Y Ichinose","year":"2003","unstructured":"Ichinose Y, Genka K, Koike T, Harubumi K, Watanabe Y, Mori T, Ilioka S, Sakuma A, Ohta M (2003) Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 95 (8): 605\u2013610","journal-title":"J Natl Cancer Inst"},{"key":"BF6605917_CR5","unstructured":"Jenkins C, Mills K, Pepper C, Burnett A (2007) Cellular aminopeptidase inhibition as a target for the therapy of AML by the novel agent tosedostat. Blood 110 (11): Abstract No. 1608"},{"key":"BF6605917_CR6","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1158\/0008-5472.CAN-07-6627","volume":"68","author":"D Krige","year":"2008","unstructured":"Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH (2008) CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 68: 6669\u20136679","journal-title":"Cancer Res"},{"issue":"1","key":"BF6605917_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markham","year":"2000","unstructured":"Markham M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel associated hypersensitivity reactions: experience of the gynecological oncology program of the cleveland clinic cancer center. J Clin Oncol 18 (1): 102\u2013105","journal-title":"J Clin Oncol"},{"issue":"4","key":"BF6605917_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1158\/1535-7163.MCT-08-0735","volume":"8","author":"HE Moore","year":"2009","unstructured":"Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE (2009) Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 8 (4): 762\u2013770","journal-title":"Mol Cancer Ther"},{"key":"BF6605917_CR9","unstructured":"Ossenkoppele G, Hooftman W, Zweegman S, Davies F, Morgan G, Mueller-Tidow C, Krug U, Duhrsen U, Burnett A, Jenkins C, Zachee P, Dierickx D, Lowenberg P, Sonneveld P, Hooftman L, Richardson A (2009) A multicentre Phase I-II study of tosedostat in the treatment of patients with relapsed or refractory acute myeloid leukaemia. Haematologica 94 (s2): Ref Type: Abstract 1065"},{"key":"BF6605917_CR10","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1158\/1078-0432.CCR-09-0306","volume":"15","author":"AH Reid","year":"2009","unstructured":"Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, De Bono JS (2009) A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Cancer Res 15: 4978\u20134985","journal-title":"Clin Cancer Res"},{"issue":"45","key":"BF6605917_CR11","doi-asserted-by":"publisher","first-page":"46723","DOI":"10.1074\/jbc.M406537200","volume":"279","author":"T Saric","year":"2004","unstructured":"Saric T, Graef CI, Goldberg AL (2004) Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279 (45): 46723\u201346732","journal-title":"J Biol Chem"},{"key":"BF6605917_CR12","first-page":"4505","volume":"46","author":"JE Talmadge","year":"1986","unstructured":"Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, Tribble H (1986) Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 46: 4505","journal-title":"Cancer Res"},{"key":"BF6605917_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van GM, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BF6605917_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker Jr JR (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263\u20131268","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605917","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:47:25Z","timestamp":1684414045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,28]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BF6605917"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605917","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,28]]}}}